PGX-YBG / Ceapro - LARVOL DELTA

Modulating pro-fibrotic macrophages using yeast beta-glucan microparticles prepared by Pressurized Gas eXpanded liquid (PGX) Technology®. (PubMed, Biomaterials) - "PGX-YBG is shown to activate Dectin-1 more efficiently in vitro while avoiding significant TLR 2/4 activation. Furthermore, PGX-YBG microparticles effectively modulate M2-like fibrosis-inducing murine and human macrophages into fibrosis-suppressing macrophages both in vitro as well as in ex vivo precision-cut murine lung slices, suggesting their potential utility as a therapeutic for addressing a broad spectrum of fibrotic end-point lung diseases."

Journal • Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • CLEC7A

Reprogramming Rogue Macrophages: Yeast Beta-glucan Microparticles as a Macrophage Modulator for Lung Fibrosis (ATS 2023) - "In vivo, PGX-YBG was intratracheally administered to the lung parenchyma of naïve and bleomycin-induced C57BL/6 mice to establish tolerability, safety, efficacy, and frequency of dosing. PGX-YBG treated BMDMs were resistant to M2 polarization, as measured by a decrease in arginase activity, and caused M2 macrophages to adopt an M1-phenotype, with increased production of TNFα and Nitrite, in a Dectin-1 dependent manner. PGX-YBG can reprogram macrophages to reduce fibrotic phenotype and has the potential to treat a broad spectrum of fibrotic end-point lung diseases."

Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • ARG1 • CCL18 • CLEC7A • IFNG • IL13 • IL4 • IL6 • TNFA

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases (GlobeNewswire) - "Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented at the American Thoracic Society (ATS) International Conference. Data demonstrated that PGX-processed yeast beta glucan (PGX-YBG) is respirable and able to safely and reliably reprogram macrophages in the lungs in pre-clinical mouse models....'This evidence, along with the latest in-vitro and in-vivo data, provides the validation that PGX-YBG holds significant potential as a therapeutic strategy for a broad spectrum of fibrotic end-point lung diseases such as COVID-19 related lung fibrosis and IPF. With these results now in hand, we are evaluating our pre-planned go/no-go decision for advancement of this program into a Phase 1 clinical trial and expect to provide updates in Q3 of this year.'"

Licensing / partnership • New P1 trial • Preclinical • Idiopathic Pulmonary Fibrosis • Interstitial Lung Disease